During the last session, Cellectar Biosciences Inc (NASDAQ:CLRB)’s traded shares were 0.8 million, with the beta value of the company hitting 0.71. At the end of the trading day, the stock’s price was $0.32, reflecting an intraday gain of 3.79% or $0.01. The 52-week high for the CLRB share is $4.22, that puts it down -1218.75 from that peak though still a striking 31.25% gain since the share price plummeted to a 52-week low of $0.22. The company’s market capitalization is $14.65M, and the average trade volume was 2.88 million shares over the past three months.
Cellectar Biosciences Inc (CLRB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.50. CLRB has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.35.
Cellectar Biosciences Inc (NASDAQ:CLRB) trade information
Cellectar Biosciences Inc (CLRB) registered a 3.79% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.79% in intraday trading to $0.32, hitting a weekly high. The stock’s 5-day price performance is 9.84%, and it has moved by 21.56% in 30 days. Based on these gigs, the overall price performance for the year is -92.15%.
The consensus price target of analysts on Wall Street is $12, which implies an increase of 97.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $12 respectively. As a result, CLRB is trading at a discount of -3650.0% off the target high and -3650.0% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 41.77%. While earnings are projected to return 48.15% in 2025, the next five years will return 32.07% per annum.
CLRB Dividends
Cellectar Biosciences Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Also, the Mutual Funds coming in first place with the largest holdings of Cellectar Biosciences Inc (CLRB) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.07 shares. This amounts to just over 2.33 percent of the company’s overall shares, with a $0.34 million market value. The same data shows that the other fund manager holds slightly less at 568.75, or about 1.23% of the stock, which is worth about $0.18 million.
